Which antiplatelet agent for whom? which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)? Current Cardiology Reports, 05/01/2012
Varenhorst C et al. – Balancing the rope between safety and efficacy of treatment is crucial for optimizing outcome. An understanding of the similarities but also differences in pharmacological effect, clinical trial design, and outcome is crucial for understanding which patient populations benefit the most from novel antiplatelet treatments. This review provides recommendations for their optimal use.